Literature DB >> 26849660

Particle Radiation Therapy for Gastrointestinal Cancers.

Makoto Shinoto1, Daniel K Ebner2,3, Shigeru Yamada4.   

Abstract

Particle irradiation of cancerous disease has gained great traction in recent years. The ability for particle therapy centers to deliver radiation with a highly conformal dose distribution while maintaining minimal exit or excess dose delivered to normal tissue, coupled with various biological advantages particularly found with heavy-ion beams, enables treatment of diseases inapproachable with conventional radiotherapy. Here, we present a review of the current status of particle therapy with regard to cancers of the gastrointestinal tract, including esophagus, liver, pancreas, and recurrent rectal cancer.

Entities:  

Keywords:  Carbon-ion radiotherapy; Gastrointestinal cancer; Particle radiotherapy; Proton beam therapy

Mesh:

Year:  2016        PMID: 26849660     DOI: 10.1007/s11912-016-0499-8

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  64 in total

1.  Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer.

Authors:  Thomas P Kole; Osarhieme Aghayere; Jason Kwah; Ellen D Yorke; Karyn A Goodman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-26       Impact factor: 7.038

2.  Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma.

Authors:  Shohei Komatsu; Takumi Fukumoto; Yusuke Demizu; Daisuke Miyawaki; Kazuki Terashima; Ryohei Sasaki; Yuichi Hori; Yoshio Hishikawa; Yonson Ku; Masao Murakami
Journal:  Cancer       Date:  2011-04-14       Impact factor: 6.860

3.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

4.  Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer.

Authors:  Makoto Shinoto; Shigeru Yamada; Shigeo Yasuda; Hiroshi Imada; Yoshiyuki Shioyama; Hiroshi Honda; Tadashi Kamada; Hirohiko Tsujii; Hiromitsu Saisho
Journal:  Cancer       Date:  2012-06-28       Impact factor: 6.860

5.  Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.

Authors:  T M Breslin; K R Hess; D B Harbison; M E Jean; K R Cleary; A P Dackiw; R A Wolff; J L Abbruzzese; N A Janjan; C H Crane; J N Vauthey; J E Lee; P W Pisters; D B Evans
Journal:  Ann Surg Oncol       Date:  2001-03       Impact factor: 5.344

6.  The use of 3-D dose volume analysis to predict radiation hepatitis.

Authors:  T S Lawrence; R K Ten Haken; M L Kessler; J M Robertson; J T Lyman; M L Lavigne; M B Brown; D J DuRoss; J C Andrews; W D Ensminger
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

7.  A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.

Authors:  Edgar Ben-Josef; Mathew Schipper; Isaac R Francis; Scott Hadley; Randall Ten-Haken; Theodore Lawrence; Daniel Normolle; Diane M Simeone; Christopher Sonnenday; Ross Abrams; William Leslie; Gazala Khan; Mark M Zalupski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-27       Impact factor: 7.038

8.  Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma.

Authors:  Madoka Morota; Kotaro Gomi; Takuyo Kozuka; Keisho Chin; Masaaki Matsuura; Masahiko Oguchi; Hisao Ito; Takashi Yamashita
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-26       Impact factor: 7.038

9.  A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors.

Authors:  Theodore S Hong; Thomas F DeLaney; Harvey J Mamon; Christopher G Willett; Beow Y Yeap; Andrzej Niemierko; John A Wolfgang; Hsiao-Ming Lu; Judith Adams; Elizabeth A Weyman; Ronald S Arellano; Lawrence S Blaszkowsky; Jill N Allen; Kenneth K Tanabe; David P Ryan; Andrew X Zhu
Journal:  Pract Radiat Oncol       Date:  2013-11-22

10.  Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma.

Authors:  Hideomi Yamashita; Hiroshi Onishi; Naoya Murakami; Yasuo Matsumoto; Yukinori Matsuo; Takuma Nomiya; Keiichi Nakagawa
Journal:  J Radiat Res       Date:  2015-02-16       Impact factor: 2.724

View more
  4 in total

1.  Current and emerging radiotherapy strategies for pancreatic adenocarcinoma: stereotactic, intensity modulated and particle radiotherapy.

Authors:  Sweet Ping Ng; Eugene J Koay
Journal:  Ann Pancreat Cancer       Date:  2018-08-13

2.  Effects of Resistance Exercise on Symptoms, Physical Function, and Quality of Life in Gastrointestinal Cancer Patients Undergoing Chemotherapy.

Authors:  Yijin Hong; Chunmei Wu; Biyu Wu
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

Review 3.  Online adaptive magnetic resonance guided radiotherapy for pancreatic cancer: state of the art, pearls and pitfalls.

Authors:  Luca Boldrini; Davide Cusumano; Francesco Cellini; Luigi Azario; Gian Carlo Mattiucci; Vincenzo Valentini
Journal:  Radiat Oncol       Date:  2019-04-29       Impact factor: 3.481

4.  Galactic Cosmic Radiation Induces Persistent Epigenome Alterations Relevant to Human Lung Cancer.

Authors:  E M Kennedy; D R Powell; Z Li; J S K Bell; B G Barwick; H Feng; M R McCrary; B Dwivedi; J Kowalski; W S Dynan; K N Conneely; P M Vertino
Journal:  Sci Rep       Date:  2018-04-30       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.